Serologic Follow-Up of a Two-Dose HPV Vaccine Schedule

Antibody persistence was noted 36 months after two-dose vaccination in children, with higher titers than those achieved with a three-dose regimen in young women.

The 9-valent human papilloma virus (HPV) vaccine protects against 90% of strains implicated in HPV-related cancers. In 2017, a two-dose regimen was approved for patients aged 9 to 14 years. Now, researchers have conducted an international study to evaluate the duration of antibody response to the two-dose regimen in boys and girls (age range, 9–14) compared with the three-dose regimen in women (age range, 16–26). In all, 1508 enrollees received two doses at baseline and 6 or 12 months, or three doses at baseline, 2 months, and 6 months.

Results at 36 months included the following:

Antibody levels in girls and boys who received vaccine at age 9 to 14 years were higher for all HPV serotypes than in women who received three doses.
Antibody levels…

Reviewing Author

Deborah Lehman, MD

Disclosures

Nothing to disclose

Deborah Lehman, MD

Disclosures

Nothing to disclose

Serologic Follow-Up of a Two-Dose HPV Vaccine Schedule

Topics

Reviewing Author